Chara Papadaki

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients

Zacharenia Saridaki, Maria Tzardi, Chara Papadaki et al. · PLoS ONE · 2011 · 125 citations · Full text

Medicine, Oncology, Pharmacology +17

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients

Ioannis Boukovinas, Chara Papadaki, Pedro Méndez et al. · PLoS ONE · 2008 · 124 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer

Maria A. Papadaki, Anastasios Koutsopoulos, Panormitis G Tsoulfas et al. · Cancers · 2020 · 90 citations · Full text

Medicine, Immunology, Oncology +17

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer

Chara Papadaki, Maria Sfakianaki, Georgios Ioannidis et al. · Journal of Thoracic Oncology · 2012 · 74 citations

Medicine, Oncology, Pharmacology +11

Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer

Chara Papadaki, Michalis Stratigos, Georgios Markakis et al. · Breast Cancer Research · 2018 · 72 citations · Full text

Medicine, Cancer Biology, Oncology +17